tergenpumatucel-L

Two Diversified Biotechs to Watch After Impressive ASCO Data
Motley Fool
Mon, 06/3/13 - 12:36 pm
ONYX Pharmaceuticals
Nexavar
tergenpumatucel-L
NewLink Genetics
ASCO
NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
Yahoo/PR Newswire
Sat, 06/1/13 - 12:19 pm
NewLink Genetics
tergenpumatucel-L
non-small cell lung cancer